buprenorphine transdermal / Generic mfg. - LARVOL DELTA

Treatment characteristics and safety profiles of Belbuca®, buprenorphine patch, and oral schedule II opioids among chronic low back pain patients without a positive history of opioid-use disorder: a retrospective US commercial claims analysis. (PubMed, Front Pain Res (Lausanne)) - "However, the buprenorphine patch cohort had higher incidence rates of serious QT prolongation (IRD -52.78 per 1,000 person-years, p = 0.009), opioid abuse/dependence (IRD -184.75 per 1,000 person-years, p < 0.001), confusion (IRR 0.10, p = 0.007), hypertension (IRR 0.22, p = 0.043), and cellulitis (IRR 0.41, p = 0.011). The study findings suggest that Belbuca® may have a favorable safety profile relative to oral CII opioids and buprenorphine patch treatments in cLBP patients without a positive history of OUD."

Journal • Retrospective data • Addiction (Opioid and Alcohol) • Back Pain • Cardiovascular • CNS Disorders • Coronary Artery Disease • Dermatology • Epilepsy • Gastroenterology • Hepatology • Hypertension • Immunology • Lumbar Back Pain • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology • Substance Abuse

Buprenorphine transdermal patch induced intractable vomiting in a low backache patient. Are unmonitored patches safe? (PubMed, Natl Med J India) - "The patch was removed promptly, and rescue antiemetics were administered. Monitoring of patients on opioids, even with TPs, is warranted."

Journal • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

Buprenorphine Products for the Treatment of Pain: Relative Risk of Abuse and Related Clinical Outcomes Compared to Full μ-Opioid Agonist Medications. (PubMed, Pain Ther) - "Findings from this study suggest that, compared to FAO, exposures to BBF managed by US poison centers were less likely to involve intentional abuse or suspected suicide, have a decreased risk of resulting in a life-threatening effect or death, and have a lower likelihood of subsequent hospital admission and emergency department visits. Along with published guidelines and medication labels (including boxed warnings), relative risks of intentional exposures and associated clinical outcomes should be considered when determining opioid therapy for pain management."

Clinical data • Journal • Relative risk • Pain

Transdermal Buprenorphine Dosing Interval Optimization from 7 Days to 5 Days: A Case Series. (PubMed, J Pain Palliat Care Pharmacother) - "Patients reported improved pain control and functionality after switching to a five-day dosing interval. Therefore, shortening the dosing interval of buprenorphine transdermal patches to five days may enhance analgesic efficacy and patient safety by minimizing end-of-dose failure and reducing the need for rescue medications."

Journal • Pain

Comparative Efficacy of Buprenorphine Transdermal Patch Versus Tramadol in Postoperative Analgesia for Shoulder Arthroscopy: a Prospective, Randomized Controlled Trial. (PubMed, Clin Ter) - "Moreover, fewer rescue analgesics were used by the buprenorphine group (10.35 ± 3.45 mg vs. 18.12 ± 4.22 mg, p = 0.04). Buprenorphine transdermal patches are effective in pain relief, more patient-satisfied, and have less side effects than oral tramadol in the postoperative treatment of shoulder arthroscopy, which makes it a promising option in postoperative analgesia."

Clinical • Journal • Orthopedics • Pain

Economic and Treatment Burden of Chronic Low-Back Pain Patients Transitioning from Short-Acting to Long-Acting Opioids or Buprenorphine Buccal Film: US Claims Analysis. (PubMed, Pain Ther) - "Study findings demonstrated similar healthcare expenditures between patients with cLBP transitioning from SAO to BBF and to LAO. Yet, initiating BBF may have lowered healthcare resource utilization and decreased further SAO utilization."

Journal • Back Pain • Human Immunodeficiency Virus • Infectious Disease • Lumbar Back Pain • Musculoskeletal Pain • Oncology • Pain

Treatment characteristics of chronic low back pain patients prescribed Belbuca® and buprenorphine transdermal patches: A retrospective US Medicare claims analysis. (PubMed, J Opioid Manag) - "The real-world evidence suggests that elderly cLBP patients may have greater benefits from Belbuca compared to the patch by achieving higher buprenorphine daily doses and decreasing opioid rescue medication use."

Journal • Medicare • Reimbursement • Retrospective data • US reimbursement • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Oncology • Pain • Substance Abuse

Buprenorphine Transdermal Patches Versus Oral Buprenorphine for the Management of Opioid Use Disorder in the Emergency Department (ASHP 2025) - No abstract available

Addiction (Opioid and Alcohol) • Substance Abuse

Buprenorphine Transdermal Patches For Opioid Use Disorder In The Emergency Department (ASHP 2025) - "Hosted by the Section of Clinical Specialists and Scientists"

Addiction (Opioid and Alcohol) • Substance Abuse

Efficacy of Buprenorphine Transdermal Patches in Chronic Pain Treatment when Transitioning from Full Opioid Agonists. (ASHP 2025) - No abstract available

Clinical • Pain

Severe Hyperphosphatemia in a Kidney Transplant Patient (KIDNEY WEEK 2025) - "Doppler ultrasound of the transplant kidney showed increased echogenicity, and elevated restive indices, no hydronephrosis...Treatment of severe hyperphosphatemia requires saline infusion, phosphate binders and hemodialysis if symptomatic. This case show the importance of close follow-up in post-transplant patients with hypophosphatemia who are taking phosphorus supplements"

Clinical • Antibody-mediated Rejection • Cardiovascular • Glomerulonephritis • Hypertension • IgA Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Transplantation

Examining Social Determinates of Health in Adult Sickle Cell Disease Patients (ASH 2024) - "Future studies should track outpatient follow-up and readmission rates over time of this patient population. Additional goals will incorporate increased screening for depression, anxiety, stress of somatic complaints to improve referrals for care as well as increased use of buprenorphine transdermal patches over excessive oral opioid use with increased risk of mortality.This project was funded by the HRSA PCTE-RTMB grant."

Clinical • Anemia • Cardiovascular • CNS Disorders • Depression • Genetic Disorders • Hematological Disorders • Mood Disorders • Psychiatry • Sickle Cell Disease

A Randomized, Open, Two-Sequence, Two-Period, Crossover Design Bioequivalence Trial of Buprenorphine Transdermal Patch in Healthy Subjects (ChiCTR) - P=N/A | N=50 | Not yet recruiting | Sponsor: Second Affiliated Hospital of Guangzhou Medical University; Yangtze River Pharmaceutical Group Zilong Pharmaceutical Co., Ltd.

New trial • Pain

Urine Drug Test Results from Patients with Chronic Pain Receiving Partial Agonist Versus Full Agonist Opioid Therapy (PAINWeek 2025) - "Purpose/Objectives : The purpose of this study was to first characterize patients managed by a pain clinic that were prescribed (1) buprenorphine buccal film (BBF), (2) buprenorphine transdermal patch (BTP), or (3) FAO therapy (including hydrocodone, hydromorphone, morphine, oxycodone, and oxymorphone) and second, evaluate the presence of illicit drugs (heroin, fentanyl, cocaine, and methamphetamine) in their urine drug tests (UDT). A total of 144,399 specimens from 35,941 unique patients and 1,022 unique providers were evaluated. BBF group had 3,675 unique patients and 9,363 specimens (average 2.55 (SD 2.83) specimens per patient); BTP group had 5,299 unique patients and 12,235 specimens (average 2.31 (SD 2.42) specimens per patient); FAO group had 26,607 unique patients and 115,606 specimens (average 4.34 (SD 4.07) specimens per patient). Females represented a majority in all study groups, though BBF (62.2%) and BTP (64.3%) patients were more likely to be female..."

Clinical • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Pain • Psychiatry • Substance Abuse

Route of Administration and Other Clinical Outcomes Among Exposures to Buprenorphine Pain Medications and Schedule II Opioids (PAINWeek 2025) - "Four study groups were studied: buprenorphine buccal film (BBF), buprenorphine transdermal patch (BTP), CII immediate-release (CII-IR) opioids, and CII extended-release (CII-ER) opioids. CII opioid compounds included solid oral dosage forms of hydrocodone, oxycodone, hydromorphone, oxymorphone, and tapentadol... From 1 January 2020 to 31 December 2023, there were 276 exposures to BBF (9 resulted in a major effect or death); 134 exposures to BTP (13 resulted in a major effect or death); 43,322 exposures to CII-IR opioids (5,519 resulted in a major effect or death); and 2,453 exposures to CII-ER opioids (435 resulted in a major effect or death) reported to NPDS. The risk of exposure resulting in major effect or death was greatest for CII-ER opioids (0.18), followed by CII-IR opioids (0.13), BTP (0.10) and lowest for BBF (0.03). Exposure resulting in major effect or death was 3.91 times (95% CI: 2.05,7.43) greater for CII-IR opioids, 5.44 times (95% CI: 2.84,10.40) greater..."

Clinical • Clinical data • Addiction (Opioid and Alcohol) • CNS Disorders • Pain

Clinical Outcomes Translated to Healthcare Costs: Comparison of Buprenorphine Pain Medications with Full-agonist Extended-Release Opioids (PAINWeek 2025) - "Buprenorphine has potentially fewer negative side effects and adverse events than other opioids used for chronic pain treatment (Adler et al., 2024), such as full-agonist opioids fentanyl, hydromorphone, morphine and oxycodone (Dalal et al., 2021)... This was an observational, cross-sectional study design with three groups: buprenorphine buccal film (BBF), buprenorphine transdermal patch (BTP) and full-agonist extended-release opioids (FA-ER; included ER oxycodone, ER hydromorphone, ER oxymorphone, and ER tapentadol)... From 01 January 2020 to 31 December 2023, there were 276 reported exposures to BBF; 134 reported exposures to BTP; and 2,453 reported exposures to FA-CII opioids. Of these, intentional abuse or misuse exposures involving BBF and BTP were similar to one another and lower than rates of FA-ER exposures: BBF intentional abuse/misuse exposures n= 41 (14.9%); BTP exposures n=19 (14.2%); and FA-ER opioid exposures n= 665 (27.1%). Percentages of admissions to a..."

Clinical • Clinical data • HEOR • Addiction (Opioid and Alcohol) • CNS Disorders • Pain • Substance Abuse

Treatment Characteristics of Chronic Low Back Pain Patients Transitioned from Oral Schedule II Short-Acting Opioids to Belbuca or Oral Schedule II Long-Acting Opioids: A Retrospective US Commercial Claims Analysis (PAINWeek 2025) - "Previously published analyses among commercial and Medicare patients with cLBP in the US focused on the comparison between Belbuca ® and the buprenorphine transdermal patch...Average daily doses were 598.1 mcg for Belbuca ® and 47.4 morphine milligram equivalents (MME) for LAO opioids...Regarding NORMs, the only observed difference was in mean duloxetine prescription counts (1.3 prescriptions in Belbuca ® vs. 1.0 prescription in LAO, p=0.042)... There were 3,350 patients identified in the database (1,331 Belbuca ® and 2,019 oral Schedule II LAO opioids). PSM yielded 964 patients in each cohort in the final study sample. During the 12-month follow-up, mean treatment durations were 156.0 days with Belbuca ® and 164.2 days with LAO opioids (p=0.180)."

Retrospective data • Addiction (Opioid and Alcohol) • Back Pain • CNS Disorders • Lumbar Back Pain • Musculoskeletal Pain • Pain

Reduction of 1,000,000 Monthly MME's to Zero Utilizing Buprenorphine and BHC Centered Care for Chronic Pain Patients in Federally Qualified Health Center: A One Year Project (PAINWeek 2025) - "Utilizing microdose formulations of buprenorphine ( Belbuca and Butrans) along with slow and thoughtful opioid taper patients can safely transition using crossover method of transition. Practice MMEs were significantly reduced month-to-month from 1 million pract ice MMEs in January 2024, to 252,000 by April 2024, 55 ,000 by J uly 2024, and ZERO by December 2024 . Some patients sought care elsewhere (about 35 %) ; many of those have returned as they have found difficulty in finding providers for full opioids . Some patients (10 -15 %) weaned off of opioids completely, including buprenorphine and are doing well on nonopioid care, often utilizing acupuncture, chiropractic, pain skills group, one-on-one counseling, and lifestyle changes (weight loss, paced exercise) ."

Clinical • Addiction (Opioid and Alcohol) • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Pain • Psychiatry • Substance Abuse

Temperature-dependent resistive switching statistics and mechanisms in nanoscale graphene-SiO2-graphene memristors. (PubMed, Nanoscale) - "As a unipolar memristor, the average set voltage (switching from a high resistive state to a low resistive state) rises with a temperature drop, while the average reset voltage (switching from a low restive state to a high state) drops slightly with the temperature drop...Statistical results suggest that the set process involves the formation of Si conducting filaments promoted by the diffusion of oxygen ions from oxygen vacancies, while the reset process involves Joule heat-driven conductive filament rupture and silicon-oxygen recombination, requiring intensified heating at higher environmental temperatures to counteract extended oxygen ion migration. Beyond general resistive switching mechanisms involving only the formation and rupture of Si conductive filaments, our insights provide a novel understanding of the stochastic mechanisms of the switching process at the atomic level, with significant implications for future neuromorphic computing applications."

Journal

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Adult Cancer Pain, Version 1.2025. (NCCN)

NCCN guideline • Oncology • Pain

Kratom Use Disorder Management Using Clonidine and/or Buprenorphine (clinicaltrials.gov) - P=N/A | N=50 | Recruiting | Sponsor: Salem Anaesthesia Pain Clinic | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date

An Exploratory Clinical Study of a Low-dose Buprenorphine Patch for the Treatment of Autism Spectrum Disorders (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: Peking University Sixth Hospital

New trial • Autism Spectrum Disorder • Genetic Disorders

CORR Insights®: Is the Use of a Buprenorphine Transdermal Patch More Effective Than Oral Medications for Postoperative Analgesia After Arthroscopic Rotator Cuff Repair? A Randomized Clinical Trial. (PubMed, Clin Orthop Relat Res) - No abstract available

Clinical • Journal • Orthopedics

Comparative Efficacy of Buprenorphine Transdermal Patch Versus Tramadol in Postoperative Analgesia for Shoulder Arthroscopy (clinicaltrials.gov) - P4 | N=70 | Active, not recruiting | Sponsor: medina medical center

New P4 trial • Musculoskeletal Pain • Orthopedics • Pain

Impact of transdermal buprenorphine patch combined with celecoxib on improving shoulder pain and function of patients with primary adhesive shoulder capsulitis. (PubMed, BMC Musculoskelet Disord) - "The combination of buprenorphine transdermal patch with celecoxib capsule may result in good analgesic efficacy and functional improvement in patients with primary ASC."

Journal • Observational data • Retrospective data • Musculoskeletal Pain • Pain